Quarterly report pursuant to Section 13 or 15(d)

Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) - Consolidated Changes in Equity (Details)

Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) - Consolidated Changes in Equity (Details) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Dec. 31, 2019	Sep. 30, 2019	Dec. 31, 2020	Dec. 31, 2019
Balances (in shares)		38,453,046			38,453,046
Balances	$ 1,439,285	$ 1,381,192			$ 1,381,192
Net earnings, including noncontrolling interest	46,144	33,395	$ 119,622		79,538	$ 134,018
Other comprehensive income	18,987	14,057	13,275		$ 33,044	$ 5,169
Common stock issued for exercise of options (in shares)					293,262	287,595
Common stock issued for exercise of options	14,268	13,728	18,295	$ 7,855
Common stock issued for restricted stock awards	0	(4,890)	0	(1,926)
Cash dividends	(12,392)	(12,336)	(12,197)	(12,169)
Stock-based compensation expense	15,471	12,667	10,017	8,267
Common stock issued to employee stock purchase plan		1,463	0	1,096
Employee stock purchase plan expense	106	286	112	99
Non-controlling interest in Eminence	$ 8,985
Balances (in shares)	38,765,300				38,765,300
Balances	$ 1,530,854	1,439,285			$ 1,530,854
Balance as of June 30, 2020 attributable to Bio-Techne		1,381,192	1,174,224	1,165,589	1,381,192	$ 1,165,589
Net earnings attributable to Bio-Techne	46,274		119,622	14,398	79,668	134,018
Other comprehensive loss	18,904		13,275	(8,106)	32,961	5,169
Balance as of December 31, 2020 attributable to Bio-Techne(3)	$ 1,521,916		$ 1,323,348	1,174,224	1,521,916	1,323,348
Cumulative Effect, Period of Adoption, Adjustment [Member]
Balances		$ (276)			$ (276)
Balance as of June 30, 2020 attributable to Bio-Techne				$ (879)		$ (879)
Common Stock [Member]
Balances (in shares)	38,601,000	38,453,000	38,084,000	37,934,000	38,453,000	37,934,000
Balances	$ 386	$ 385			$ 385
Net earnings, including noncontrolling interest
Other comprehensive income
Common stock issued for exercise of options (in shares)		117,000	195,000	94,000
Common stock issued for exercise of options	$ 2	$ 1	$ 2	$ 1
Common stock issued for restricted stock awards (in shares)	3,000	25,000	4,000	50,000
Common stock issued for restricted stock awards	$ 0	$ 0	$ 0	$ 0
Cash dividends
Stock-based compensation expense
Common stock issued to employee stock purchase plan (in shares)	161,000	6,000		6,000
Common stock issued to employee stock purchase plan		$ 0		$ 0
Employee stock purchase plan expense
Non-controlling interest in Eminence
Balances (in shares)	38,765,000	38,601,000	38,283,000	38,084,000	38,765,000	38,283,000
Balances	$ 388	$ 386			$ 388
Balance as of June 30, 2020 attributable to Bio-Techne			$ 381	$ 379		$ 379
Balance as of December 31, 2020 attributable to Bio-Techne(3)			383	381		383
Common Stock [Member] \| Cumulative Effect, Period of Adoption, Adjustment [Member]
Balances
Additional Paid-in Capital [Member]
Balances	448,679	420,536			420,536
Net earnings, including noncontrolling interest
Other comprehensive income
Common stock issued for exercise of options	16,748	13,727	18,293	7,854
Common stock issued for restricted stock awards	(0)	(0)	(0)	(0)
Cash dividends
Stock-based compensation expense	15,471	12,667	10,017	8,267
Common stock issued to employee stock purchase plan		1,463		1,096
Employee stock purchase plan expense	106	286	112	99
Non-controlling interest in Eminence
Balances	481,004	448,679			481,004
Balance as of June 30, 2020 attributable to Bio-Techne			334,112	316,797		316,797
Balance as of December 31, 2020 attributable to Bio-Techne(3)			362,534	334,112		362,534
Additional Paid-in Capital [Member] \| Cumulative Effect, Period of Adoption, Adjustment [Member]
Balances
Retained Earnings [Member]
Balances	1,073,362	1,057,470			1,057,470
Net earnings, including noncontrolling interest	46,274	33,395
Other comprehensive income
Common stock issued for exercise of options	(2,482)
Common stock issued for restricted stock awards	0	(4,890)		(1,926)
Cash dividends	(12,392)	(12,336)	(12,197)	(12,169)
Stock-based compensation expense
Common stock issued to employee stock purchase plan
Employee stock purchase plan expense
Non-controlling interest in Eminence
Balances	1,104,762	1,073,362			1,104,762
Balance as of June 30, 2020 attributable to Bio-Techne			931,358	931,934		931,934
Net earnings attributable to Bio-Techne			119,622	14,398
Balance as of December 31, 2020 attributable to Bio-Techne(3)			1,038,783	931,358		1,038,783
Retained Earnings [Member] \| Cumulative Effect, Period of Adoption, Adjustment [Member]
Balances		(276)			(276)
Balance as of June 30, 2020 attributable to Bio-Techne				(879)		(879)
AOCI Attributable to Parent [Member]
Balances	(83,142)	(97,199)			(97,199)
Net earnings, including noncontrolling interest
Other comprehensive income	18,904	14,057
Common stock issued for exercise of options
Common stock issued for restricted stock awards
Cash dividends
Stock-based compensation expense
Common stock issued to employee stock purchase plan
Employee stock purchase plan expense
Non-controlling interest in Eminence
Balances	(64,238)	(83,142)			(64,238)
Balance as of June 30, 2020 attributable to Bio-Techne			(91,627)	(83,521)		(83,521)
Other comprehensive loss			13,275
Balance as of December 31, 2020 attributable to Bio-Techne(3)			$ (78,352)	$ (91,627)		$ (78,352)
AOCI Attributable to Parent [Member] \| Cumulative Effect, Period of Adoption, Adjustment [Member]
Balances
Noncontrolling Interest [Member]
Balances	0	0			0
Net earnings, including noncontrolling interest	(130)
Other comprehensive income	83
Common stock issued for exercise of options
Common stock issued for restricted stock awards
Cash dividends
Stock-based compensation expense
Common stock issued to employee stock purchase plan
Employee stock purchase plan expense
Non-controlling interest in Eminence	8,985
Balances	$ 8,938	0			8,938
Noncontrolling Interest [Member] \| Cumulative Effect, Period of Adoption, Adjustment [Member]
Balances